Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure – a prospective, double-blind, placebo-controlled trial
Intensive Care MedicinePublished 12 April 2001
Johan Van der Spoel, H. Oudemans-van Straaten, C. P. Stoutenbeek, Rob J. Bosman, D. F. Zandstra
Citations189
SJR quartileQ1
SJR score5.00
SNIP6.11
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Overall, in none of the patients did passage of stools occur during placebo infusion, whereas 19 of the 24 neostigmine-treated patients had defecation, but three patients had ischemic colonic complications 7–10 days after treatment.
Abstract
Continuous infusion of 0.4-0.8 mg/h of neostigmine promotes defecation in ICU patients with a colonic ileus without important adverse reactions.
Keywords
Medicine